ReviewMolecular therapy oncolytics2022
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy.
Review in Molecular therapy oncolytics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06056791 (An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Who cites it
41 citing papers in PubMed.
- In vivo immune cell engineering from bench to clinical reality.Pharmaceutical science advances · 2026Review
- PTPN22 as a novel therapeutic target: a key intracellular checkpoint for NK cell therapy.Journal for immunotherapy of cancer · 2026Article
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Non-viral targeted integration at the CISH locus enables CAR-NK cell engineering with enhanced anti-tumor activity.Molecular therapy. Oncology · 2026Article
- Genetic manipulation of OGT enhances NK cell-mediated cytotoxicity in tumor immunity.Journal of advanced research · 2026Article
- Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy.Annals of hematology · 2026Review
- CAR-NK cell therapy for hematologic malignancies: advances, challenges and optimization strategies.Molecular cancer · 2026Review
- Transcriptional networks weaving natural killer anti-tumor immune response.Molecular cancer · 2026Review
- Harnessing CAR-Extracellular Vesicles for Next-Generation Cancer Immunotherapy.International journal of molecular sciences · 2026Review
- Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.The AAPS journal · 2026Review
- Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication.Cancer cell international · 2026Review
- Defining treatment-resistant brain cancer: Genetic screening to identify oncogene-driven immunomodulation and therapy resistance.Cancer gene therapy · 2026Review
- BaEV-pseudotyped lentiviral vectors enable stable CAR expression and cytotoxic function in NK cells.PloS one · 2026Article
- Immune cell-based therapies for solid tumors, current challenges and therapeutic advances.Cell communication and signaling : CCS · 2025Review
- Multidimensional plasticity of natural killer cells in tumours.Cell death & disease · 2025Review
- CAR-NK Engineering to Overcome TME Barriers.Cells · 2025Review
- Overcoming barriers in CAR-NK immunotherapy: CRISPR-Driven advances in checkpoint editing and allogeneic design.Functional & integrative genomics · 2025Review
- Review
- CAR-Based Cell and Gene Therapies: Global Clinical Landscape and Emerging Therapeutic Strategies from ClinicalTrials.gov.Biomolecules & therapeutics · 2025Review
- Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.Immunotherapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of many cancers, particularly those that remain difficult to treat or are refractive after standard-of-care therapies, has been challenging with cell-based therapies. Although relatively safe as allogeneic therapies and innately effective against cancers without the need for antigen sensitization, natural killer (NK) cells have necessitated use of genetic manipulation approaches to enhance their specificity, persistence, and homing. Chimeric antigen receptor (CAR) and gene-edited NK cell therapies have emerged as a potent treatment modality, addressing many of the issues that have plagued such gene-based therapies with other cell types. Early examples of engineered NK cell therapies have largely leveraged their activity against hematological malignancies in combination with conventional construct architectures or by editing putative genetic targets of immunosuppression. As the motivation to tackle more complex solid tumors grows, so has the sophistication and emergence of NK-specific constructs and engineering approaches. Multi-CARs, combinations with diverse genome editing technologies, as well as responsive and sensing CARs have appeared in the context of NK cell therapy. Here we discuss engineering approaches for NK cell therapy, the latest developments in the field, and what stands in the way of those promises en route to clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.